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Hemizygous deletions at chromosomal location 16q22.1 frequently occur in many human cancers, 
including more than 50% of all breast cancers.  One of the genes in this locus, CTCF, is critical for 
chromatin organization and acts as a master regulator of the genome. While the prevailing opinion in 
the field is that deletion of both copies of a tumor suppressor is necessary for oncogenesis, Drs. 
Chris Kemp and Gala Filippova (Human Biology Division), together with Brady Bernard and Ilya 
Shmulevich (Institute for Systems Biology) as well as Matt Teater and Ari Melnick (Cornell 
University), demonstrate that loss of a single copy of Ctcf triggers epigenetic changes and markedly 
increases cancer development and progression in mice and humans. 
CTCF is a well-conserved zinc finger DNA-binding protein that binds several different target 
sequences across the genome to establish chromatin boundaries and facilitate chromatin-chromatin 
interactions. This protein also mediates multiple epigenetic phenomena including genomic 
imprinting, X chromosome inactivation, and regulation of spreading DNA methylation (Filippova, 
2008). Human CTCF, a gene that was originally cloned at the Fred Hutchinson Cancer Research 
Center, was mapped to 16q22.1 more than 15 years ago (Filippova, 1998); however, a causal 
relationship between the partial loss of CTCF and oncogenesis was yet to be established. 
To investigate the possibility that hemizygous deletion of Ctcf drives tumor progression, the 
researchers developed a Ctcf knockout mouse line. Ctcf
-/-
 was embryonic lethal, confirming that 
CTCF is critical for development (Moore, 2012); however, Ctcf
+/-
 mice were essentially normal. 
Interestingly, Ctcf
+/-
 mice developed twice as many cancers as their wildtype littermates, and were 
three-times more likely to develop multiple tumors. These tumors also occurred in a variety of tissue 
types and were phenotypically more aggressive than those forming in wildtype mice. Similar patterns 
of tumor development were observed when Ctcf
+/-
 mice were exposed to various oncogenic 
treatments, such as irradiation or chemical mutagenesis.  
All Ctcf
+/-
 mouse tumors that were examined retained a single wildtype Ctcf allele with no mutations 
or deletions in the coding region, confirming that CTCF is truly haploinsufficient for tumor 
suppression. To investigate the mechanism underlying this haploinsufficiency, the researchers  
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defined the methylation state of wildtype and mutant genomes. Ctcf
+/-
 mice had alterations in CpG 
methylation that tended towards hypermethylation at multiple distinct sites across the genome 
relative to wildtype controls. These changes preceded the development of cancer, suggesting that 
the epigenetic changes may set the stage for tumor development. The authors next analyzed human 
tumors in the Cancer Genome Atlas (TCGA) and found that 57% of human breast tumors and 24% 
of uterine endometrial cancers contained hemizygous CTCF deletions. CTCF was also the 16th and 
4th most mutated gene in these cancers, respectively. Similar to the mouse tumors, CTCF
+/-
 human 
tumors also contained distinct CpG methylation differences across the genome, suggesting that the 
oncogenic mechanism may be conserved across species. 
This study by Kemp, et al. clearly demonstrates that the epigenetic regulator CTCF is a potent tumor 
suppressor. The loss of a single allele of Ctcf, and the accompanying epigenetic instability, was 
sufficient to drive aggressive tumor formation in a variety of tissues. Data from TCGA analysis 
suggested that CTCF copy number variation may occur preferentially in some cancer subtypes. 
Going forward, "we should determine if tumors with loss of CTCF, with their distinct epigenetic 
profile, have different responses to therapy," said Dr. Gala Filippova. 
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Image adapted from Kemp, et al., 2014. 
Deletion of a single Ctcf allele in mice (left) led to alterations in DNA methylation and increased 
oncogenesis. Human tumors of the breast and uterus (right) had frequent loss of a single allele of 
CTCF and similar changes in genomic methylation patterns. 
 
